GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs

[IPO Ahead Financial Growth]
narvo vexar

Weight loss drug developer Kailera Therapeutics (KLRA [https://seekingalpha.com/symbol/KLRA]) and Alamar Biosciences (ALMR [https://seekingalpha.com/symbol/ALMR]), a commercial-stage proteomics company, filed for their respective U.S. initial public offerings with the SEC on Friday.

Waltham, Massachusetts-based Kailera (KLRA [https://seekingalpha.com/symbol/KLRA]), which has four GLP-1 candidates in the pipeline, says in the S-1 filing that it intends to list on the Nasdaq Global Select Market under the symbol "KLRA."

Kailera’s (KLRA [https://seekingalpha.com/symbol/KLRA]) lead candidate, ribupatide, developed [https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm] with Chinese pharma Jiangsu Hengrui Pharmaceuticals (JHPCY [https://seekingalpha.com/symbol/JHPCY]) (JNGHF [https://seekingalpha.com/symbol/JNGHF]), is currently undergoing three Phase 3 trials for obese or overweight adults, with topline data expected in 2028.

The GLP-1/GIP receptor dual agonist, as a once-weekly injectable, has caused up to 19.2% of average weight loss across three dose levels in a 48-week Phase 3 trial conducted by Hengrui in China.

The company incurred a $149.0M net loss in 2025, driven by $109.1M in R&D expenses, following a $219.7M net loss recorded in the prior year from its inception on May 8, 2024.

Meanwhile, Fremont, California-headquartered Alamar (ALMR [https://seekingalpha.com/symbol/ALMR]), which specializes in protein detection and analysis, filed with the SEC for its proposed U.S. IPO on the Nasdaq Global Market under the ticker symbol “ALMR.”

According to its S-1 filing, the company has generated $74.2M in revenue in 2025 with over 195% YoY growth thanks to its ARGO HT System, a research-use-only product designed to automate proteomics analysis [https://www.sec.gov/Archives/edgar/data/2104204/000119312526129039/d39680ds1.htm]. Since its inception in 2018, Alamar (ALMR [https://seekingalpha.com/symbol/ALMR]) has incurred net losses, and in 2025, its net loss narrowed ~37% YoY to $29.8M.

MORE ON KAILERA THERAPEUTICS, INC., ALAMAR BIOSCIENCES, INC.

* Financial information for Kailera Therapeutics, Inc. [https://seekingalpha.com/symbol/KLRA/income-statement]
* Financial information for Alamar Biosciences, Inc. [https://seekingalpha.com/symbol/ALMR/income-statement]